Global OAB Treatment

OAB Treatment Comprehensive Study by Type (Lifestyle Changes, Prescription Medications, Bladder Botox Treatment, Nerve Stimulation, Surgery), Application (Hospitals, Clinics, Others), Disease (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), Diagnosis (Medical History, Physical Examination, Urine Sample test, Focused Neurological Examination) Players and Region - Global Market Outlook to 2030

OAB Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About OAB Treatment
Overactive bladder (OAB) is a syndrome that causes a sudden, involuntary contraction of the muscle in the wall of the urinary bladder. The urge to urinate may be difficult to stop and overactive bladder may lead to the involuntary loss of urine. This syndrome affects both men and women and can significantly impact the quality of life. There are several treatments are available for overactive bladder such as pelvic-muscle strengthening, behavioral therapies, medications, neuromodulation, and surgery.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The overactive bladder treatment market is moderately competitive due to the presence of several players in the market. Some of the key players in the market are AbbVie Inc. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global OAB Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (United States), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan) and Sanofi (France) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Aurobindo Pharma Limited (India), Apotex, Inc. (Canada) and Cogentix Medical, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global OAB Treatment market by Type (Lifestyle Changes, Prescription Medications, Bladder Botox Treatment, Nerve Stimulation and Surgery), Application (Hospitals, Clinics and Others) and Region.



On the basis of geography, the market of OAB Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Disease, the sub-segment i.e. Idiopathic Bladder Overactivity will boost the OAB Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. Medical History will boost the OAB Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in the Field of Medical Science

Market Growth Drivers:
Increased Prevalence of Urinary Tract Diseases and Development of New Diagnostic Centre and Hospitals

Challenges:
Less Awareness about OAB Syndrome

Restraints:
Undesired Systemic Effects of Current OAB Treatments

Opportunities:
Growing Geriatric Population Worldwide and Development of Healthcare Infrastructure in Emerging Economies

Market Leaders and their expansionary development strategies
In January 2020, Astellas Pharma Inc. has announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics, Inc., an AAV-based genetic medicines company focused on developing and commercializing innovative therapies that can offer transformative benefits to patients.
In June 2017 - Astellas Pharma Inc. President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of mirabegron in combination with solifenacin succinate 5 mg for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.


Key Target Audience
OAB Treatment Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Lifestyle Changes
  • Prescription Medications
  • Bladder Botox Treatment
  • Nerve Stimulation
  • Surgery
By Application
  • Hospitals
  • Clinics
  • Others
By Disease
  • Idiopathic Bladder Overactivity
  • Neurogenic Bladder Overactivity

By Diagnosis
  • Medical History
  • Physical Examination
  • Urine Sample test
  • Focused Neurological Examination

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Urinary Tract Diseases
      • 3.2.2. Development of New Diagnostic Centre and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness about OAB Syndrome
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in the Field of Medical Science
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global OAB Treatment, by Type, Application, Disease, Diagnosis and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global OAB Treatment (Value)
      • 5.2.1. Global OAB Treatment by: Type (Value)
        • 5.2.1.1. Lifestyle Changes
        • 5.2.1.2. Prescription Medications
        • 5.2.1.3. Bladder Botox Treatment
        • 5.2.1.4. Nerve Stimulation
        • 5.2.1.5. Surgery
      • 5.2.2. Global OAB Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Others
      • 5.2.3. Global OAB Treatment by: Disease (Value)
        • 5.2.3.1. Idiopathic Bladder Overactivity
        • 5.2.3.2. Neurogenic Bladder Overactivity
      • 5.2.4. Global OAB Treatment by: Diagnosis (Value)
        • 5.2.4.1. Medical History
        • 5.2.4.2. Physical Examination
        • 5.2.4.3. Urine Sample test
        • 5.2.4.4. Focused Neurological Examination
      • 5.2.5. Global OAB Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. OAB Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma, Inc. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Limited (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan, Plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medtronic plc (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Mylan N.V. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Endo International plc (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global OAB Treatment Sale, by Type, Application, Disease, Diagnosis and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global OAB Treatment (Value)
      • 7.2.1. Global OAB Treatment by: Type (Value)
        • 7.2.1.1. Lifestyle Changes
        • 7.2.1.2. Prescription Medications
        • 7.2.1.3. Bladder Botox Treatment
        • 7.2.1.4. Nerve Stimulation
        • 7.2.1.5. Surgery
      • 7.2.2. Global OAB Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Others
      • 7.2.3. Global OAB Treatment by: Disease (Value)
        • 7.2.3.1. Idiopathic Bladder Overactivity
        • 7.2.3.2. Neurogenic Bladder Overactivity
      • 7.2.4. Global OAB Treatment by: Diagnosis (Value)
        • 7.2.4.1. Medical History
        • 7.2.4.2. Physical Examination
        • 7.2.4.3. Urine Sample test
        • 7.2.4.4. Focused Neurological Examination
      • 7.2.5. Global OAB Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. OAB Treatment: by Type(USD Million)
  • Table 2. OAB Treatment Lifestyle Changes , by Region USD Million (2018-2023)
  • Table 3. OAB Treatment Prescription Medications , by Region USD Million (2018-2023)
  • Table 4. OAB Treatment Bladder Botox Treatment , by Region USD Million (2018-2023)
  • Table 5. OAB Treatment Nerve Stimulation , by Region USD Million (2018-2023)
  • Table 6. OAB Treatment Surgery , by Region USD Million (2018-2023)
  • Table 7. OAB Treatment: by Application(USD Million)
  • Table 8. OAB Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 9. OAB Treatment Clinics , by Region USD Million (2018-2023)
  • Table 10. OAB Treatment Others , by Region USD Million (2018-2023)
  • Table 11. OAB Treatment: by Disease(USD Million)
  • Table 12. OAB Treatment Idiopathic Bladder Overactivity , by Region USD Million (2018-2023)
  • Table 13. OAB Treatment Neurogenic Bladder Overactivity , by Region USD Million (2018-2023)
  • Table 14. OAB Treatment: by Diagnosis(USD Million)
  • Table 15. OAB Treatment Medical History , by Region USD Million (2018-2023)
  • Table 16. OAB Treatment Physical Examination , by Region USD Million (2018-2023)
  • Table 17. OAB Treatment Urine Sample test , by Region USD Million (2018-2023)
  • Table 18. OAB Treatment Focused Neurological Examination , by Region USD Million (2018-2023)
  • Table 19. South America OAB Treatment, by Country USD Million (2018-2023)
  • Table 20. South America OAB Treatment, by Type USD Million (2018-2023)
  • Table 21. South America OAB Treatment, by Application USD Million (2018-2023)
  • Table 22. South America OAB Treatment, by Disease USD Million (2018-2023)
  • Table 23. South America OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 24. Brazil OAB Treatment, by Type USD Million (2018-2023)
  • Table 25. Brazil OAB Treatment, by Application USD Million (2018-2023)
  • Table 26. Brazil OAB Treatment, by Disease USD Million (2018-2023)
  • Table 27. Brazil OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 28. Argentina OAB Treatment, by Type USD Million (2018-2023)
  • Table 29. Argentina OAB Treatment, by Application USD Million (2018-2023)
  • Table 30. Argentina OAB Treatment, by Disease USD Million (2018-2023)
  • Table 31. Argentina OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 32. Rest of South America OAB Treatment, by Type USD Million (2018-2023)
  • Table 33. Rest of South America OAB Treatment, by Application USD Million (2018-2023)
  • Table 34. Rest of South America OAB Treatment, by Disease USD Million (2018-2023)
  • Table 35. Rest of South America OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 36. Asia Pacific OAB Treatment, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific OAB Treatment, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific OAB Treatment, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific OAB Treatment, by Disease USD Million (2018-2023)
  • Table 40. Asia Pacific OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 41. China OAB Treatment, by Type USD Million (2018-2023)
  • Table 42. China OAB Treatment, by Application USD Million (2018-2023)
  • Table 43. China OAB Treatment, by Disease USD Million (2018-2023)
  • Table 44. China OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 45. Japan OAB Treatment, by Type USD Million (2018-2023)
  • Table 46. Japan OAB Treatment, by Application USD Million (2018-2023)
  • Table 47. Japan OAB Treatment, by Disease USD Million (2018-2023)
  • Table 48. Japan OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 49. India OAB Treatment, by Type USD Million (2018-2023)
  • Table 50. India OAB Treatment, by Application USD Million (2018-2023)
  • Table 51. India OAB Treatment, by Disease USD Million (2018-2023)
  • Table 52. India OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 53. South Korea OAB Treatment, by Type USD Million (2018-2023)
  • Table 54. South Korea OAB Treatment, by Application USD Million (2018-2023)
  • Table 55. South Korea OAB Treatment, by Disease USD Million (2018-2023)
  • Table 56. South Korea OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 57. Taiwan OAB Treatment, by Type USD Million (2018-2023)
  • Table 58. Taiwan OAB Treatment, by Application USD Million (2018-2023)
  • Table 59. Taiwan OAB Treatment, by Disease USD Million (2018-2023)
  • Table 60. Taiwan OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 61. Australia OAB Treatment, by Type USD Million (2018-2023)
  • Table 62. Australia OAB Treatment, by Application USD Million (2018-2023)
  • Table 63. Australia OAB Treatment, by Disease USD Million (2018-2023)
  • Table 64. Australia OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific OAB Treatment, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific OAB Treatment, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific OAB Treatment, by Disease USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 69. Europe OAB Treatment, by Country USD Million (2018-2023)
  • Table 70. Europe OAB Treatment, by Type USD Million (2018-2023)
  • Table 71. Europe OAB Treatment, by Application USD Million (2018-2023)
  • Table 72. Europe OAB Treatment, by Disease USD Million (2018-2023)
  • Table 73. Europe OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 74. Germany OAB Treatment, by Type USD Million (2018-2023)
  • Table 75. Germany OAB Treatment, by Application USD Million (2018-2023)
  • Table 76. Germany OAB Treatment, by Disease USD Million (2018-2023)
  • Table 77. Germany OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 78. France OAB Treatment, by Type USD Million (2018-2023)
  • Table 79. France OAB Treatment, by Application USD Million (2018-2023)
  • Table 80. France OAB Treatment, by Disease USD Million (2018-2023)
  • Table 81. France OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 82. Italy OAB Treatment, by Type USD Million (2018-2023)
  • Table 83. Italy OAB Treatment, by Application USD Million (2018-2023)
  • Table 84. Italy OAB Treatment, by Disease USD Million (2018-2023)
  • Table 85. Italy OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 86. United Kingdom OAB Treatment, by Type USD Million (2018-2023)
  • Table 87. United Kingdom OAB Treatment, by Application USD Million (2018-2023)
  • Table 88. United Kingdom OAB Treatment, by Disease USD Million (2018-2023)
  • Table 89. United Kingdom OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 90. Netherlands OAB Treatment, by Type USD Million (2018-2023)
  • Table 91. Netherlands OAB Treatment, by Application USD Million (2018-2023)
  • Table 92. Netherlands OAB Treatment, by Disease USD Million (2018-2023)
  • Table 93. Netherlands OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 94. Rest of Europe OAB Treatment, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe OAB Treatment, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe OAB Treatment, by Disease USD Million (2018-2023)
  • Table 97. Rest of Europe OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 98. MEA OAB Treatment, by Country USD Million (2018-2023)
  • Table 99. MEA OAB Treatment, by Type USD Million (2018-2023)
  • Table 100. MEA OAB Treatment, by Application USD Million (2018-2023)
  • Table 101. MEA OAB Treatment, by Disease USD Million (2018-2023)
  • Table 102. MEA OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 103. Middle East OAB Treatment, by Type USD Million (2018-2023)
  • Table 104. Middle East OAB Treatment, by Application USD Million (2018-2023)
  • Table 105. Middle East OAB Treatment, by Disease USD Million (2018-2023)
  • Table 106. Middle East OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 107. Africa OAB Treatment, by Type USD Million (2018-2023)
  • Table 108. Africa OAB Treatment, by Application USD Million (2018-2023)
  • Table 109. Africa OAB Treatment, by Disease USD Million (2018-2023)
  • Table 110. Africa OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 111. North America OAB Treatment, by Country USD Million (2018-2023)
  • Table 112. North America OAB Treatment, by Type USD Million (2018-2023)
  • Table 113. North America OAB Treatment, by Application USD Million (2018-2023)
  • Table 114. North America OAB Treatment, by Disease USD Million (2018-2023)
  • Table 115. North America OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 116. United States OAB Treatment, by Type USD Million (2018-2023)
  • Table 117. United States OAB Treatment, by Application USD Million (2018-2023)
  • Table 118. United States OAB Treatment, by Disease USD Million (2018-2023)
  • Table 119. United States OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 120. Canada OAB Treatment, by Type USD Million (2018-2023)
  • Table 121. Canada OAB Treatment, by Application USD Million (2018-2023)
  • Table 122. Canada OAB Treatment, by Disease USD Million (2018-2023)
  • Table 123. Canada OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 124. Mexico OAB Treatment, by Type USD Million (2018-2023)
  • Table 125. Mexico OAB Treatment, by Application USD Million (2018-2023)
  • Table 126. Mexico OAB Treatment, by Disease USD Million (2018-2023)
  • Table 127. Mexico OAB Treatment, by Diagnosis USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. OAB Treatment: by Type(USD Million)
  • Table 138. OAB Treatment Lifestyle Changes , by Region USD Million (2025-2030)
  • Table 139. OAB Treatment Prescription Medications , by Region USD Million (2025-2030)
  • Table 140. OAB Treatment Bladder Botox Treatment , by Region USD Million (2025-2030)
  • Table 141. OAB Treatment Nerve Stimulation , by Region USD Million (2025-2030)
  • Table 142. OAB Treatment Surgery , by Region USD Million (2025-2030)
  • Table 143. OAB Treatment: by Application(USD Million)
  • Table 144. OAB Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 145. OAB Treatment Clinics , by Region USD Million (2025-2030)
  • Table 146. OAB Treatment Others , by Region USD Million (2025-2030)
  • Table 147. OAB Treatment: by Disease(USD Million)
  • Table 148. OAB Treatment Idiopathic Bladder Overactivity , by Region USD Million (2025-2030)
  • Table 149. OAB Treatment Neurogenic Bladder Overactivity , by Region USD Million (2025-2030)
  • Table 150. OAB Treatment: by Diagnosis(USD Million)
  • Table 151. OAB Treatment Medical History , by Region USD Million (2025-2030)
  • Table 152. OAB Treatment Physical Examination , by Region USD Million (2025-2030)
  • Table 153. OAB Treatment Urine Sample test , by Region USD Million (2025-2030)
  • Table 154. OAB Treatment Focused Neurological Examination , by Region USD Million (2025-2030)
  • Table 155. South America OAB Treatment, by Country USD Million (2025-2030)
  • Table 156. South America OAB Treatment, by Type USD Million (2025-2030)
  • Table 157. South America OAB Treatment, by Application USD Million (2025-2030)
  • Table 158. South America OAB Treatment, by Disease USD Million (2025-2030)
  • Table 159. South America OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 160. Brazil OAB Treatment, by Type USD Million (2025-2030)
  • Table 161. Brazil OAB Treatment, by Application USD Million (2025-2030)
  • Table 162. Brazil OAB Treatment, by Disease USD Million (2025-2030)
  • Table 163. Brazil OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 164. Argentina OAB Treatment, by Type USD Million (2025-2030)
  • Table 165. Argentina OAB Treatment, by Application USD Million (2025-2030)
  • Table 166. Argentina OAB Treatment, by Disease USD Million (2025-2030)
  • Table 167. Argentina OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 168. Rest of South America OAB Treatment, by Type USD Million (2025-2030)
  • Table 169. Rest of South America OAB Treatment, by Application USD Million (2025-2030)
  • Table 170. Rest of South America OAB Treatment, by Disease USD Million (2025-2030)
  • Table 171. Rest of South America OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 172. Asia Pacific OAB Treatment, by Country USD Million (2025-2030)
  • Table 173. Asia Pacific OAB Treatment, by Type USD Million (2025-2030)
  • Table 174. Asia Pacific OAB Treatment, by Application USD Million (2025-2030)
  • Table 175. Asia Pacific OAB Treatment, by Disease USD Million (2025-2030)
  • Table 176. Asia Pacific OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 177. China OAB Treatment, by Type USD Million (2025-2030)
  • Table 178. China OAB Treatment, by Application USD Million (2025-2030)
  • Table 179. China OAB Treatment, by Disease USD Million (2025-2030)
  • Table 180. China OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 181. Japan OAB Treatment, by Type USD Million (2025-2030)
  • Table 182. Japan OAB Treatment, by Application USD Million (2025-2030)
  • Table 183. Japan OAB Treatment, by Disease USD Million (2025-2030)
  • Table 184. Japan OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 185. India OAB Treatment, by Type USD Million (2025-2030)
  • Table 186. India OAB Treatment, by Application USD Million (2025-2030)
  • Table 187. India OAB Treatment, by Disease USD Million (2025-2030)
  • Table 188. India OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 189. South Korea OAB Treatment, by Type USD Million (2025-2030)
  • Table 190. South Korea OAB Treatment, by Application USD Million (2025-2030)
  • Table 191. South Korea OAB Treatment, by Disease USD Million (2025-2030)
  • Table 192. South Korea OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 193. Taiwan OAB Treatment, by Type USD Million (2025-2030)
  • Table 194. Taiwan OAB Treatment, by Application USD Million (2025-2030)
  • Table 195. Taiwan OAB Treatment, by Disease USD Million (2025-2030)
  • Table 196. Taiwan OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 197. Australia OAB Treatment, by Type USD Million (2025-2030)
  • Table 198. Australia OAB Treatment, by Application USD Million (2025-2030)
  • Table 199. Australia OAB Treatment, by Disease USD Million (2025-2030)
  • Table 200. Australia OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific OAB Treatment, by Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific OAB Treatment, by Application USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific OAB Treatment, by Disease USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 205. Europe OAB Treatment, by Country USD Million (2025-2030)
  • Table 206. Europe OAB Treatment, by Type USD Million (2025-2030)
  • Table 207. Europe OAB Treatment, by Application USD Million (2025-2030)
  • Table 208. Europe OAB Treatment, by Disease USD Million (2025-2030)
  • Table 209. Europe OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 210. Germany OAB Treatment, by Type USD Million (2025-2030)
  • Table 211. Germany OAB Treatment, by Application USD Million (2025-2030)
  • Table 212. Germany OAB Treatment, by Disease USD Million (2025-2030)
  • Table 213. Germany OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 214. France OAB Treatment, by Type USD Million (2025-2030)
  • Table 215. France OAB Treatment, by Application USD Million (2025-2030)
  • Table 216. France OAB Treatment, by Disease USD Million (2025-2030)
  • Table 217. France OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 218. Italy OAB Treatment, by Type USD Million (2025-2030)
  • Table 219. Italy OAB Treatment, by Application USD Million (2025-2030)
  • Table 220. Italy OAB Treatment, by Disease USD Million (2025-2030)
  • Table 221. Italy OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 222. United Kingdom OAB Treatment, by Type USD Million (2025-2030)
  • Table 223. United Kingdom OAB Treatment, by Application USD Million (2025-2030)
  • Table 224. United Kingdom OAB Treatment, by Disease USD Million (2025-2030)
  • Table 225. United Kingdom OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 226. Netherlands OAB Treatment, by Type USD Million (2025-2030)
  • Table 227. Netherlands OAB Treatment, by Application USD Million (2025-2030)
  • Table 228. Netherlands OAB Treatment, by Disease USD Million (2025-2030)
  • Table 229. Netherlands OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 230. Rest of Europe OAB Treatment, by Type USD Million (2025-2030)
  • Table 231. Rest of Europe OAB Treatment, by Application USD Million (2025-2030)
  • Table 232. Rest of Europe OAB Treatment, by Disease USD Million (2025-2030)
  • Table 233. Rest of Europe OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 234. MEA OAB Treatment, by Country USD Million (2025-2030)
  • Table 235. MEA OAB Treatment, by Type USD Million (2025-2030)
  • Table 236. MEA OAB Treatment, by Application USD Million (2025-2030)
  • Table 237. MEA OAB Treatment, by Disease USD Million (2025-2030)
  • Table 238. MEA OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 239. Middle East OAB Treatment, by Type USD Million (2025-2030)
  • Table 240. Middle East OAB Treatment, by Application USD Million (2025-2030)
  • Table 241. Middle East OAB Treatment, by Disease USD Million (2025-2030)
  • Table 242. Middle East OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 243. Africa OAB Treatment, by Type USD Million (2025-2030)
  • Table 244. Africa OAB Treatment, by Application USD Million (2025-2030)
  • Table 245. Africa OAB Treatment, by Disease USD Million (2025-2030)
  • Table 246. Africa OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 247. North America OAB Treatment, by Country USD Million (2025-2030)
  • Table 248. North America OAB Treatment, by Type USD Million (2025-2030)
  • Table 249. North America OAB Treatment, by Application USD Million (2025-2030)
  • Table 250. North America OAB Treatment, by Disease USD Million (2025-2030)
  • Table 251. North America OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 252. United States OAB Treatment, by Type USD Million (2025-2030)
  • Table 253. United States OAB Treatment, by Application USD Million (2025-2030)
  • Table 254. United States OAB Treatment, by Disease USD Million (2025-2030)
  • Table 255. United States OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 256. Canada OAB Treatment, by Type USD Million (2025-2030)
  • Table 257. Canada OAB Treatment, by Application USD Million (2025-2030)
  • Table 258. Canada OAB Treatment, by Disease USD Million (2025-2030)
  • Table 259. Canada OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 260. Mexico OAB Treatment, by Type USD Million (2025-2030)
  • Table 261. Mexico OAB Treatment, by Application USD Million (2025-2030)
  • Table 262. Mexico OAB Treatment, by Disease USD Million (2025-2030)
  • Table 263. Mexico OAB Treatment, by Diagnosis USD Million (2025-2030)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global OAB Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global OAB Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global OAB Treatment: by Disease USD Million (2018-2023)
  • Figure 7. Global OAB Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 8. South America OAB Treatment Share (%), by Country
  • Figure 9. Asia Pacific OAB Treatment Share (%), by Country
  • Figure 10. Europe OAB Treatment Share (%), by Country
  • Figure 11. MEA OAB Treatment Share (%), by Country
  • Figure 12. North America OAB Treatment Share (%), by Country
  • Figure 13. Global OAB Treatment share by Players 2023 (%)
  • Figure 14. Global OAB Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global OAB Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Astellas Pharma, Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 18. Astellas Pharma, Inc. (Japan) Revenue: by Geography 2023
  • Figure 19. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Teva Pharmaceutical Industries Limited (Israel) Revenue, Net Income and Gross profit
  • Figure 22. Teva Pharmaceutical Industries Limited (Israel) Revenue: by Geography 2023
  • Figure 23. Allergan, Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Allergan, Plc (Ireland) Revenue: by Geography 2023
  • Figure 25. Medtronic plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 26. Medtronic plc (Ireland) Revenue: by Geography 2023
  • Figure 27. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Mylan N.V. (United States) Revenue: by Geography 2023
  • Figure 29. Endo International plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 30. Endo International plc (Ireland) Revenue: by Geography 2023
  • Figure 31. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 32. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2023
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2023
  • Figure 35. Global OAB Treatment: by Type USD Million (2025-2030)
  • Figure 36. Global OAB Treatment: by Application USD Million (2025-2030)
  • Figure 37. Global OAB Treatment: by Disease USD Million (2025-2030)
  • Figure 38. Global OAB Treatment: by Diagnosis USD Million (2025-2030)
  • Figure 39. South America OAB Treatment Share (%), by Country
  • Figure 40. Asia Pacific OAB Treatment Share (%), by Country
  • Figure 41. Europe OAB Treatment Share (%), by Country
  • Figure 42. MEA OAB Treatment Share (%), by Country
  • Figure 43. North America OAB Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Astellas Pharma, Inc. (Japan)
  • Pfizer, Inc. (United States)
  • Teva Pharmaceutical Industries Limited (Israel)
  • Allergan, Plc (Ireland)
  • Medtronic plc (Ireland)
  • Mylan N.V. (United States)
  • Endo International plc (Ireland)
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Sanofi (France)
Additional players considered in the study are as follows:
Aurobindo Pharma Limited (India) , Apotex, Inc. (Canada) , Cogentix Medical, Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 207 Pages 91 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global OAB Treatment Quantitative research analysis
Global OAB Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Astellas Pharma, Inc. (Japan), Pfizer, Inc. (United States), Teva Pharmaceutical Industries Limited (Israel), Allergan, Plc (Ireland), Medtronic plc (Ireland), Mylan N.V. (United States), Endo International plc (Ireland), Hisamitsu Pharmaceutical Co., Inc. (Japan) and Sanofi (France) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in the Field of Medical Science" is seen as one of major influencing trends for OAB Treatment Market during projected period 2023-2030.
The OAB Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global OAB Treatment Report?

Have a Query? Click Here

Other Related Reports

Depth of Anesthesia Monitoring Comprehensive Study by Type (Devices, Consumables), Application (Fluid Management, Cesarean Section, Laparoscopic Surgery, Vascular Surgery, Orthopedic Surgery, Cardiol...
$ 3750
Fibromyalgia Treatment Comprehensive Study by Type (Symptomatic, Targeted), Application (Hospitals Pharmacies, Clinic Pharmacy, Retail Drug Stores, Online Pharmacies), Medication Type (Antidepressant...
$ 3650
Moyamoya disease Comprehensive Study by Type (Ischemic, Hemorrhagic, Epileptic, Other), Treatment (Non-Surgical {Anti-seizure medications, and Calcium channel blockers}, Surgical {Vascular bypass sur...
$ 3750
Bacteriophages Therapy Comprehensive Study by Type (Lytic, Lysogenic), Application (Diagnostic, Antimicrobial Drug Discovery, Veterinary Medicines, Others), Treatment (Oral, External Application, Sur...
$ 3650
Systemic Mycoses Comprehensive Study by Type (Paracoccidioides, Blastomyces, Histoplasma, Coccidiode), Fungi (Dermatophytes, Yeasts, Molds), Drugs (Amphotericin B, Amphotericin B Itraconazole, Amphot...
$ 3750
Neurotrophic Keratitis Treatment Comprehensive Study by Type (Drugs, Devices, Surgery), Application (Hospitals, Ambulatory Surgical Centers, Others), Route of Administration (Oral, Topical), Distribu...
$ 3450